We used the TGFBR1 specific inhibitor Galunisertib, which was investigated in a phase 2 trial to treat HCC, a small-molecule cancer drug that specifically inhibits TGF-beta signaling 31, 32. The gene discussed is TGFBR1; the disease is cancer.